FT-207 (NSC 148958) , ≥98%(HPLC) , 17902-23-7

Synonym(s):
5-Fluoro-1-(tetrahydro-2-furyl)uracil;Ftorafur;Tegafur

CAS NO.：17902-23-7

Empirical Formula: C8H9FN2O3

Molecular Weight: 200.17

MDL number: MFCD00012351

EINECS: 241-846-2

PRODUCT Properties

• Melting point: 171-173 °C(lit.)
• Density: 1.3222 (estimate)
• storage temp.: room temp
• solubility: DMSO: >50mg/mL
• form: Very Fine Crystalline Powder
• pka: 7.63±0.10(Predicted)
• color: white to off-white
• Merck: 14,9112
• InChIKey: WFWLQNSHRPWKFK-UHFFFAOYSA-N
• CAS DataBase Reference: 17902-23-7(CAS DataBase Reference)
• EPA Substance Registry System: 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)- (17902-23-7)

Description and Uses

Tegafur is an orally bioavailable prodrug form of 5-fluorouracil (5-FU; ). It is converted to 5-FU in vivo enzymatically or by cytochrome P450 oxidation. Tegafur inhibits proliferation of HT-29, BxPC-3, and Panc02 cells (IC₅₀s = 201, 172, and 179 μM, respectively). It also reduces tumor growth in an HT-27 colon carcinoma mouse xenograft model when administered at a dose of 50 mg/kg and in a 4-1ST gastric carcinoma mouse xenograft model when used in combination with uracil. Formulations containing tegafur, in combination with uracil, have been used in the treatment of cancer.

Isotope labelled Tegafur (T013900), used as an antineoplastic.

Safety

• Symbol(GHS): GHS06
• Signal word: Danger
• Hazard statements: H301+H311+H331
• Precautionary statements: P261-P264-P280-P301+P310-P302+P352+P312-P304+P340+P311
• Hazard Codes: T
• Risk Statements: 23/24/25
• Safety Statements: 22-36/37/39-45
• RIDADR: UN 2811 6.1/PG 2
• WGK Germany: 3
• RTECS: YR0450000
• HazardClass: 6.1
• PackingGroup: II
• HS Code: 29349990
• Toxicity: LD50 in mice (mg/kg): 900 orally (3 days) (Yasumoto); 750 i.p. (FR 1574684), also reported as 1150 i.p. (Smart)